Previous 10 | Next 10 |
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combinati...
2023-12-13 17:30:39 ET The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference . If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize. At the December Fed meeting, the central bank has caused a significa...
2023-12-12 12:16:51 ET DENVER, Colo., Dec. 12, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aditxt Inc (NASDAQ: ADTX), C4 Therapeutics Inc. (NASDAQ: CCCC), IN8bio Inc. (NASDAQ: INAB), Petros Pha...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced ...
2023-11-30 15:11:10 ET More on Agenus, GSK, etc. Getting_Ahead_of_Respiratory_Diseases_Slides GSK plc (GSK) Getting Ahead of Respiratory Diseases Event with GSK Management Conference (Transcript) GSK plc (GSK) Presents at Redburn Atlantic CEO Conference (Transcript) ...
2023-11-07 06:50:04 ET More on Agenus Agenus: Getting The Tough Decisions Right With Catalysts Ahead Agenus: Immuno-Oncology Advancements Amidst Fiscal Pressures Agenus to cut 25% staff as lead program takes priority Seeking Alpha’s Quant Rating on Age...
Conference Call on Tuesday, November 7, 2023, at 9:00 a.m. ET Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. Agenus executives will host ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Agenus Inc. (AGEN) is expected to report $-0.19 for Q3 2023
2023-11-06 11:50:20 ET More on Agenus Agenus: Getting The Tough Decisions Right With Catalysts Ahead Agenus: Immuno-Oncology Advancements Amidst Fiscal Pressures Agenus to cut 25% staff as lead program takes priority Seeking Alpha’s Quant Rating on Age...
News, Short Squeeze, Breakout and More Instantly...
New analysis highlights BOT/BAL activity across challenging metastatic disease sites Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab ...
Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-...
2024-05-16 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...